Display Settings:

Format

Send to:

Choose Destination
    Infect Dis Obstet Gynecol. 2011;2011:963513. Epub 2011 Jun 26.

    Chlamydia trachomatis vaccine research through the years.

    Source

    Department of Molecular Biotechnology, Faculty of Bioscience Engineering, Ghent University, Coupure Links 653, 9000 Ghent, Belgium. katelijn.schautteet@ugent.be

    Abstract

    Chlamydia trachomatis is a Gram-negative obligate intracellular bacterium. It is the leading cause of bacterial sexual transmitted infections (STIs). World Health Organization figures estimated that over 90 million new cases of genital C. trachomatis infections occur worldwide each year. A vaccination program is considered to be the best approach to reduce the prevalence of C. trachomatis infections, as it would be much cheaper and have a greater impact on controlling C. trachomatis infections worldwide rather than a screening program or treating infections with antibiotics. Currently, there are no vaccines available which effectively protect against a C. trachomatis genital infection despite the many efforts that have been made throughout the years. In this paper, the many attempts to develop a protective vaccine against a genital C. trachomatis infection will be reviewed.

    PMID:
    21747646
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC3124257
    Free PMC Article

      Supplemental Content

      Icon for Hindawi Publishing Corporation Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk